Opicapone for Parkinson's disease-related sleep disturbances: The OASIS clinical trial.

IF 4 3区 医学 Q2 NEUROSCIENCES
Journal of Parkinson's disease Pub Date : 2025-02-01 Epub Date: 2025-01-17 DOI:10.1177/1877718X241306711
Joaquim J Ferreira, Miguel F Gago, Raquel Costa, Miguel M Fonseca, Joana Almeida, José Francisco Rocha, Joerg Holenz, Claudia Trenkwalder
{"title":"Opicapone for Parkinson's disease-related sleep disturbances: The OASIS clinical trial.","authors":"Joaquim J Ferreira, Miguel F Gago, Raquel Costa, Miguel M Fonseca, Joana Almeida, José Francisco Rocha, Joerg Holenz, Claudia Trenkwalder","doi":"10.1177/1877718X241306711","DOIUrl":null,"url":null,"abstract":"<p><p>BackgroundWhile sleep disturbances are among the most frequent non-motor symptoms of Parkinson's disease (PD), there is a lack of evidence to support its treatment.ObjectiveTo evaluate the efficacy of opicapone 50 mg in treating sleep disturbances in patients with PD and end-of-dose motor fluctuations.MethodsOASIS was an exploratory, open-label, single-arm clinical trial in PD patients with end-of-dose motor fluctuations and associated sleep disturbances. The primary endpoint was change from baseline to week 6 in Parkinson's Disease Sleep Scale 2 (PDSS-2). Secondary endpoints included functional motor and non-motor assessments (Movement Disorder Society [MDS]-Unified Parkinson's Disease Rating Scale [UPDRS], MDS-Non-motor Scale [NMS], 8-item PD Questionnaire [PDQ-8], 16-item PD Fatigue Scale [PFS-16], ON/OFF home diary), Clinical and Patient Global Impression of Change (CGI-C; PGI-C) and adverse events.ResultsAt week 6, there was a significant reduction of -7.9 points (95%CI -13.6, -2.2; <i>p</i> = 0.0099) in PDSS-2 total score, with a significant mean change of -4.7 in the PDSS-2 domain of disturbed sleep (95%CI: -7.2, -2.3; <i>p</i> = 0.0009). Significant reductions were also observed in PFS-16 (-9.6; <i>p</i> = 0.0211), MDS-NMS total score (-28.9; <i>p</i> = 0.0015), MDS-UPDRS-III (-6.3; <i>p</i> = 0.0253), MDS-UPDRS-IV (-1.2; <i>p</i> = 0.0044) and PDQ-8 (-14.2; <i>p</i> = 0.0051). Absolute OFF-time was reduced (-142.1 min). Most patients (93.3%) and most clinicians (80.0%) reported improvements on PGI-C and CGI-C, respectively. Opicapone was well tolerated.ConclusionsAdding opicapone 50 mg to levodopa/DDCI therapy in patients with PD and motor fluctuations and sleep disturbances improved both sleep disturbances and OFF time in these patients.</p>","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":" ","pages":"87-96"},"PeriodicalIF":4.0000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Parkinson's disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/1877718X241306711","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/17 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
引用次数: 0

Abstract

BackgroundWhile sleep disturbances are among the most frequent non-motor symptoms of Parkinson's disease (PD), there is a lack of evidence to support its treatment.ObjectiveTo evaluate the efficacy of opicapone 50 mg in treating sleep disturbances in patients with PD and end-of-dose motor fluctuations.MethodsOASIS was an exploratory, open-label, single-arm clinical trial in PD patients with end-of-dose motor fluctuations and associated sleep disturbances. The primary endpoint was change from baseline to week 6 in Parkinson's Disease Sleep Scale 2 (PDSS-2). Secondary endpoints included functional motor and non-motor assessments (Movement Disorder Society [MDS]-Unified Parkinson's Disease Rating Scale [UPDRS], MDS-Non-motor Scale [NMS], 8-item PD Questionnaire [PDQ-8], 16-item PD Fatigue Scale [PFS-16], ON/OFF home diary), Clinical and Patient Global Impression of Change (CGI-C; PGI-C) and adverse events.ResultsAt week 6, there was a significant reduction of -7.9 points (95%CI -13.6, -2.2; p = 0.0099) in PDSS-2 total score, with a significant mean change of -4.7 in the PDSS-2 domain of disturbed sleep (95%CI: -7.2, -2.3; p = 0.0009). Significant reductions were also observed in PFS-16 (-9.6; p = 0.0211), MDS-NMS total score (-28.9; p = 0.0015), MDS-UPDRS-III (-6.3; p = 0.0253), MDS-UPDRS-IV (-1.2; p = 0.0044) and PDQ-8 (-14.2; p = 0.0051). Absolute OFF-time was reduced (-142.1 min). Most patients (93.3%) and most clinicians (80.0%) reported improvements on PGI-C and CGI-C, respectively. Opicapone was well tolerated.ConclusionsAdding opicapone 50 mg to levodopa/DDCI therapy in patients with PD and motor fluctuations and sleep disturbances improved both sleep disturbances and OFF time in these patients.

求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
8.40
自引率
5.80%
发文量
338
审稿时长
>12 weeks
期刊介绍: The Journal of Parkinson''s Disease (JPD) publishes original research in basic science, translational research and clinical medicine in Parkinson’s disease in cooperation with the Journal of Alzheimer''s Disease. It features a first class Editorial Board and provides rigorous peer review and rapid online publication.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信